32 results about "Hepatic metastasis" patented technology

The application discloses a multi-omics pathological analysis system and method for predicting the risk of colorectal liver metastasis, relates to the technical field of biomedical and cancer diagnosis, and comprises a data acquisition module, a data preprocessing module, a cell analysis module, a score construction module, a model construction and training module and a prediction and evaluation module; the application realizes comprehensive and accurate prediction of the risk of colorectal liver metastasis by integrating multi-omics data, including single-cell data sets, spatial transcriptome data, batch RNA-seq data, clinical data and whole slide image WSIs; the cross-dimension data fusion and analysis not only improve the accuracy and reliability of prediction, but also provide a powerful tool for in-depth exploration of the molecular mechanism of tumor occurrence, development and metastasis, especially in the cell analysis module, identification and analysis of the malignant cell subpopulation LMTMCs triggering liver metastasis can reveal cell subtypes and molecular characteristics closely related to liver metastasis, thereby providing a scientific basis for formulating a personalized treatment plan.

The application belongs to the technical field of biotechnology, and particularly relates to a colorectal cancer high liver metastasis cell line and a preparation method and application thereof. The cell line was preserved in the China Center for Type Culture Collection on January 14, 2026, and the preservation number is CCTCC NO: C202618. The cell line is derived from a mouse colorectal cancer cell line MC38, and is constructed by lentivirus transfection to express luciferase stably, and is obtained by continuously performing at least five rounds of liver metastasis tumor orthotopic iteration screening in C57BL / 6 mice through rectal submucosal injection. The MC38-P06 cell line provided by the application has a significantly enhanced liver metastasis ability, a shorter MC38-P01 model time, a higher liver tumor load, and a shorter mouse survival period, and can be used for screening and evaluating anti-liver metastasis drugs, researching liver microenvironment regulation mechanisms, and identifying liver metastasis related diagnostic markers.

The invention belongs to the technical field of tumor prognosis prediction, and relates to a colorectal cancer allotropic liver metastasis prediction method and system.The method comprises the steps that colorectal adenocarcinoma cases are collected, the volume of an intra-tumor region-of-interest is delineated and automatically expanded to generate the volume of a peritumor region-of-interest, image omics characteristics are extracted through a pyradiomics packet, core omics characteristics are screened out, and the colorectal cancer allotropic liver metastasis prediction result is obtained. The method comprises the following steps: respectively constructing an intratumoral model and a peritumoral model, analyzing and integrating intratumoral and peritumoral core omics characteristics through logistic regression to form a combined radiomics model, integrating the combined radiomics model and clinical risk factors, establishing a column diagram for predicting the non-hepatic metastasis lifetime, and dividing patients into a low-risk group and a high-risk group according to a column diagram score threshold value; according to the method, LMFS prediction results of 1-5 years can be quickly output, and 0.6911 is set as a standardized risk stratification cut-off value so as to support risk stratification and personalized treatment decision of a patient.

The invention belongs to the technical field of biomedicine, and particularly relates to a flora marker for predicting colorectal cancer liver metastasis and application of the flora marker. According to the present invention, the bacterial group marker is the combination of Acinetobacter, Streptococcus, Pseudomonas, Brevundimonas and Sphingomonas, and the bacterial group marker combination provides extremely high specificity (95.29%) and sensitivity (91.43%) when the early liver metastasis of colorectal cancer is predicted, such that the liver metastasis risk of the patient can be accurately assisted in the determination, and the early liver metastasis risk of the colorectal cancer can be accurately determined; the method has the advantages that reliable basis is provided for clinical decision making, the colorectal cancer liver metastasis can be predicted only by taking the abundance of the specific bacteria as an input index, the method is not limited by specific measurement means, and dependence on a detection technology is greatly reduced.

This invention discloses the application of a branched-chain amino acid (BCAA) restricted diet in the preparation of drugs for treating liver metastases of tumors. Through mouse model experiments, this invention found that restricting the intake of BCAAs (valine, isoleucine, and leucine) in the diet, or using the SCD1 inhibitor A939572, can significantly inhibit liver metastases of tumors, especially pancreatic cancer liver metastases. Experimental results show that a BCAA restricted diet or SCD1 inhibitor can reduce the number and volume of liver metastases and inhibit their growth. This invention also reveals its mechanism of action: BCAA restriction reduces the propionylation modification of SREBP1, downregulates the transcriptional expression of its target gene SCD1, and thus reduces lipid synthesis, thereby exerting an anti-tumor liver metastasis effect. This invention provides a novel dietary intervention strategy and drug target for the treatment of liver metastases of tumors.

The present application relates to the application of an oncolytic virus carrying interleukin 10 in the field of colorectal cancer liver metastasis. The present application provides the use of a recombinant oncolytic virus in the preparation of a drug for treating colorectal cancer liver metastasis, wherein the recombinant oncolytic virus expresses interleukin 10. The recombinant oncolytic virus provided in the present application can overcome the immune clearance of the virus and the immunosuppression of the liver metastasis in the treatment of colorectal cancer liver metastasis, thereby improving the treatment effect of colorectal cancer liver metastasis.

The present application relates to the field of animal model construction, and in particular to a melanoma liver metastasis model construction method, which uses a spleen injection method to construct a human melanoma A375-M1 cell line liver metastasis model, and is identified in vivo by PET-CT and MRI, and is identified ex vivo by Bouin's and H&E.The human melanoma liver metastasis tumor model constructed by the present application has the advantages of short construction time, simple method and 100% modeling success rate.This metastasis model simulates the development process and pathological characteristics of melanoma liver metastasis, solves the problem of the lack of an ideal animal model for human melanoma during liver metastasis, and helps to explore and screen the development of anti-liver metastasis drugs for human melanoma, and plays a positive promoting role in new strategies for anti-melanoma liver metastasis.

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecule compounds having a 6,6-heterocyclic structure (e.g., compounds having a naphthyridine, pyrido-pyridazine, pyrido-pyrazine, quinoline, pyrazino-pyridazine, pyrimido-pyrimidine, quinazoline, quinoxaline or cinnoline ring system) which function as inhibitors of DYRK1A, DYRK1B, DYRK2, DYRK3, CLK1, CLK2, CLK3, CLK4, CDK7, CDK8 / 19, PI3K, PDGFrA / B, mTOR, WNT, homeodomain-interacting kinases (HIPKs), and / or CMGC kinases leading to inhibition of WNT signaling, and their use as therapeutics for the treatment of Alzheimer's disease, down syndrome, Parkinson's disease, Huntington's disease, diabetes, autoimmune diseases, inflammatory disorders (e.g., airway inflammation, osteoarthritis (e.g., knee related osteoarthritis)), cancer (e.g., glioblastoma, prostate cancer, metastatic breast cancer, metastatic lung cancer, multiple myeloma, secondary metastatic tumors of the brain, colorectal cancer and metastatic colorectal cancer (e.g., metastatic colorectal cancer in the liver)), and other diseases.

The invention belongs to the field of biological medicine, and particularly relates to application of nicotinic acid and derivatives thereof in prevention or treatment of colorectal cancer growth and metastasis. It is found for the first time that nicotinic acid and novel derivatives thereof can effectively and remarkably inhibit proliferation, migration and invasion of colorectal cancer cells, and can inhibit growth and liver metastasis of the colorectal cancer cells in a mouse model. Experiments prove that the medicine reagent prepared from the nicotinic acid or the combination of the nicotinic acid and other medicines is safe and effective, and a new thought is provided for preparing the medicines for preventing or treating the liver cancer.

The invention relates to the technical field of antitumor drugs, and particularly discloses application and a composition of an iron transporter inhibitor (VIT-2763). The invention provides an application of an iron transporter inhibitor VIT-2763 in preparation of a medicine for preventing and treating tumor metastasis. The iron transporter inhibitor VIT-2763 can obviously inhibit liver metastasis of colorectal cancer and has the potential of being used as a medicine for resisting liver metastasis of colorectal cancer. Meanwhile, the invention further provides a composition for resisting colorectal cancer liver metastasis, the composition comprises the iron transporter inhibitor VIT-2763 and oxaliplatin, and when the iron transporter inhibitor VIT-2763 and the oxaliplatin are combined for use, the drug resistance of colorectal cancer cells to the oxaliplatin can be improved, the sensitivity of liver metastatic colorectal cancer cells to the oxaliplatin is remarkably improved, and the curative effect is good. The treatment effect of resisting colorectal cancer liver metastasis is synergistically enhanced, and the technical problem that an existing treatment means lacks a specific intervention means for colorectal cancer liver metastasis is solved.

The invention relates to application of icaritin combined with one or two of a PD-1 antibody and albumin paclitaxel in preparation of a medicine for treating advanced colorectal cancer, particularly colorectal cancer with liver metastasis. The combined medicine can be applied to medicines for relieving advanced colorectal cancer, particularly colorectal cancer with liver metastasis.

The invention provides application of a PTGIS gene and / or PTGIS protein in preparation of medicines for treating colorectal cancer and preventing and treating liver metastasis of colorectal cancer. The invention proves that PTGIS obviously inhibits colorectal cancer liver metastasis for the first time, and in-vitro and animal experiments show that proliferation, migration and liver metastasis load of colorectal cancer cells can be reduced through overexpression of PTGIS; meanwhile, the immunotherapy effect can be further enhanced by combining the PTGIS and the PD-L1 antibody, and the curative effect is superior to that of a single drug. PTGIS is expected to become a novel intervention target, provides a new molecular regulation thought for immune combined treatment of colorectal cancer liver metastasis, and has theoretical and transformation values.

This invention provides a combination of bile protein biomarkers for predicting liver metastasis of pancreatic cancer and its application. The combination of bile protein biomarkers includes at least MMP9, PRTN3, and S100A12. This application transforms bile, previously considered biological waste, into a high-value diagnostic sample. Based on the differences in bile proteins among patients with benign disease, patients with pancreatic cancer without liver metastasis, and patients with pancreatic cancer with liver metastasis, four optimal biomarker combinations are screened for the first time to establish a method for predicting the risk of pancreatic cancer liver metastasis for early preoperative assessment of pancreatic cancer liver metastasis risk.

The human liver metastasis-derived colon cancer cell line CRC-X1 and its application belong to the field of microbial animal cell lines. The human colon cancer cell line is named Homo sapiens CRC-X1, and was preserved in the China Center for Type Culture Collection on November 22, 2025, with the preservation number CCTCC NO: C2025354. The human liver metastasis-derived colon cancer cell line CRC-X1 can be applied in the establishment of a cell model of colon cancer occurrence, development or metastasis; CRC-X1 can be applied in the cell model of studying the differentiation mechanism of colon cancer, cell morphology and functional abnormalities, tumor infiltration and metastasis mechanism, and guiding clinical comprehensive diagnosis and treatment. CRC-X1 can be applied in the study of the mechanism of colon cancer and the screening of drugs for preventing and treating colon cancer. CRC-X1 can be applied in the establishment of an animal model of colon cancer.

This invention discloses a CD33-blocking humanized antibody and its uses. The CD33-blocking humanized antibody comprises a heavy chain and a light chain; the heavy chain includes a variable region, the amino acid sequence of which is shown in SEQ ID NO. 20; the light chain includes a variable region, the amino acid sequence of which is shown in SEQ ID NO. 21. This invention also discloses a method for preparing the CD33-blocking humanized antibody, obtained by humanizing a rabbit CD33 antibody. Furthermore, it discloses the application of the CD33-blocking humanized antibody in the preparation of drugs for inhibiting liver metastasis of neuroendocrine prostate cancer and small cell lung cancer. The CD33-blocking humanized antibody of this invention exhibits high affinity and high specificity for CD33, and demonstrates excellent therapeutic and inhibitory effects on liver metastasis of neuroendocrine prostate cancer and small cell lung cancer.

The invention belongs to the field of biological pharmacy, and particularly discloses application of evodiamine in inhibition of migration and invasion of gallbladder cancer cells and metastatic tumor growth. Aiming at the problems of poor drug targeting, high toxicity, easy drug resistance and the like in gallbladder cancer hepatic metastasis treatment, the invention provides various application forms of evodiamine: 1) an evodiamine single-drug sustained release preparation (PLGA or chitosan carrier) realizes long-acting sustained release through local intervention or intratumor injection; 2) the evodiamine liposome preparation (the ratio of DPPC to cholesterol is 3: 1, and the particle size is 80-150nm) can improve the enrichment rate of hepatic metastatic focus to 5.8% or above; (3) the evodiamine and chemotherapeutic drugs (oxaliplatin, 5-FU and the like) are combined to form a composition, and the synergy index is Cilt; 0.8, the toxicity of the system is obviously reduced; animal experiments show that the liver metastasis inhibition rate reaches 82.7% and the weight loss rate is only 10.5% when the liposome (3 mg / kg of evodiamine and 6 mg / kg of oxaliplatin) is combined, and a high-efficiency and low-toxicity solution is provided for gallbladder carcinoma metastasis.

The invention belongs to the technical field of disease prognosis and molecular biology, and relates to a flora marker for colorectal cancer liver metastasis diagnosis and liver metastasis risk assessment and application of the flora marker. The marker comprises the following three strains: bifidobacterium bifidum, bacteroides fragilis and bacteroides heparinidolyticus. The method comprises the following steps: acquiring information of microorganisms in excrement of a patient through a high-resolution metagenomics detection technology; a random forest algorithm is utilized to construct a colorectal cancer liver metastasis classification model based on the flora markers, the model can distinguish people without colorectal cancer metastasis and people with liver metastasis and accurately predict high-risk patients with colorectal cancer liver metastasis, and the effect of the model is superior to that of a clinical conventional tumor serum marker. The kit has the advantages of noninvasive detection and high accuracy, and can provide a reliable tool for liver metastasis diagnosis and individualized prognosis management of colorectal cancer patients.

The application belongs to the technical field of medical image processing and artificial intelligence, and discloses a colorectal cancer liver metastasis risk assessment method and system based on multi-modal fusion. The method comprises the following steps: obtaining preoperative abdominal computed tomography (CT) images and clinical pathological data of a patient; pre-processing the CT images, segmenting a three-dimensional region of interest, and extracting radiomics features, and standardizing the clinical data; inputting the radiomics features into a first prediction model to obtain an imaging score, and inputting the clinical data into a second prediction model to obtain a clinical score; based on a preset fusion strategy, the two scores are weighted and fused, and a comprehensive risk score of postoperative liver metastasis of the patient is output as auxiliary assessment information. The application can accurately assist in assessing the risk of colorectal cancer liver metastasis after surgery by non-invasively and efficiently integrating CT image quantitative features and clinical information, and provides an objective decision-making tool for clinicians to develop individualized diagnosis and treatment plans and follow-up strategies.

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecule compounds having a 6,6-heterocyclic structure (e.g., compounds having a naphthyridine, pyrido-pyridazine, pyrido-pyrazine, quinoline, pyrazino-pyridazine, pyrimido-pyrimidine, quinazoline, quinoxaline or cinnoline ring system) which function as inhibitors of DYRK1A, DYRK1B, DYRK2, DYRK3, CLK1, CLK2, CLK3, CLK4, CDK7, CDK8 / 19, PI3K, PDGFrA / B, mTOR, WNT, homeodomain-interacting kinases (HIPKs), and / or CMGC kinases leading to inhibition of WNT signaling, and their use as therapeutics for the treatment of Alzheimer's disease, down syndrome, Parkinson's disease, Huntington's disease, diabetes, autoimmune diseases, inflammatory disorders (e.g., airway inflammation, osteoarthritis (e.g., knee related osteoarthritis)), cancer (e.g., glioblastoma, prostate cancer, metastatic breast cancer, metastatic lung cancer, multiple myeloma, secondary metastatic tumors of the brain, colorectal cancer and metastatic colorectal cancer (e.g., metastatic colorectal cancer in the liver)), and other diseases.

The invention provides a composition for reversing drug resistance of a small cell lung cancer hepatic metastatic ferroptosis inducer and application of the composition, and belongs to the technical field of biological medicine. The composition for reversing the drug resistance of the small cell lung cancer hepatometastatic ferroptosis inducer provided by the invention comprises the ferroptosis inducer and a GPX4 inhibitor. The composition can remarkably reverse the drug resistance of a ferroptosis inducer induced by a liver microenvironment, reduce the dosage of the ferroptosis inducer and improve the detection sensitivity and reproducibility through the synergistic effect of improving the lipid peroxidation pressure and reducing the scavenging capacity, and the mechanism specificity is proved to have a good application prospect through a Fer-1 rescue test. The medicine is suitable for small cell lung cancer people with or with high-risk liver metastasis, and a new effective strategy is provided for clinical treatment.

The application discloses a kind of based on space omics's intestinal cancer metastasis prediction method, device, medium and equipment, method includes: acquisition original multi-omics data, modal alignment and quality control processing are handled, obtain including second spatial transcriptome data, second single-cell RNA sequencing data and second pathology image data pre-processing multi-omics data;Second single-cell RNA sequencing data is based on second spatial transcriptome data and is carried out cross-modal semantic embedding, generates space enhanced expression profile;Second spatial transcriptome data and second pathology image data are carried out multi-scale graph construction, and spatial heterogeneity feature is extracted;Space enhanced expression profile and spatial heterogeneity feature are input into pre-trained metastasis risk prediction model, and output liver metastasis probability space heat map and key driving feature list;Finally generate the clinical prediction report containing high-risk area positioning.The application significantly improves the sensitivity of early metastasis detection by dynamically optimizing spatial resolution and multi-scale feature collaborative modeling.

The present application belongs to the technical field of intelligent medical treatment, and particularly relates to a RAS, BRAF gene wild type colorectal cancer liver metastasis patient curative effect prediction model based on image group characteristics and application thereof. The present application successfully constructs a model for realizing curative effect prediction of RAS, BRAF gene wild type colorectal cancer liver metastasis patients receiving bevacizumab combined with chemotherapy treatment in the late first line based on CT image group characteristics before treatment: the enhanced CT image group data before initial treatment of patients with advanced colorectal cancer liver metastasis at the time of initial diagnosis is collected, 7 image group characteristics are obtained by using 1000 times Lasso-Logistic analysis, and an image group prediction model is constructed by using a multi-factor logistic regression method. The model constructed by the present application has important clinical application and popularization value from the clinical actual problem.

The invention provides a method for applying a Dual-input ViT model to colorectal cancer hepatic metastatic focus treatment response prediction, and relates to the field of image processing. The method comprises the following steps: S1) constructing a structured image tag data set, sketching a liver metastasis focus ROI on a double-time-point enhanced CT image of a colorectal cancer liver metastasis patient, and carrying out data processing on the double-time-point enhanced CT image and the liver metastasis focus ROI; step S2), constructing a Dual-input ViT model based on a DDFM (Double Data Frequency Modulation); s3) constructing a joint loss function to carry out constraint optimization on the Dual-input ViT model based on the DDFM, carrying out supervised training based on a curative effect response label, and then verifying the Dual-input ViT model through an ablation experiment; and S4) reasoning by using the trained dual-input ViT model based on the DDFM, and predicting the treatment effectiveness of the colorectal cancer liver metastases. According to the application, the change forms of the lesions before and after the treatment can be dynamically captured, and the sensitivity of curative effect prediction is improved.

The invention discloses a colorectal cancer metastasis marker, a corresponding detection kit and application. The marker is one or more of IFI44, CXCL8 and MBL2. Database data and actual clinical data show that the colorectal cancer metastasis marker has good sensitivity and specificity in diagnosis of colorectal cancer metastasis, especially liver metastasis and lung metastasis.

The invention discloses tsRNA (transfer ribonucleic acid) and application thereof. The nucleotide sequence of the tsRNA is as shown in SEQ ID NO: 1. The novel tsRNA molecule provided by the invention can be accurately used for diagnosing the bladder cancer, and meanwhile, after the tRF3-16-AlaAGC-1 is knocked down, proliferation and migration of bladder cancer cells can be inhibited, the activity of the bladder cancer cells can be reduced, the liver metastasis rate of the bladder cancer cells can be reduced, and a novel powerful molecular biological tool is provided for treatment of the bladder cancer. The method has profound clinical significance and important popularization and application prospects.

The invention discloses an early prediction biomarker and a prediction model for colorectal cancer liver metastasis, the biomarker is an exosome RNA derived from plasma, and the biomarker comprises at least one of HRC, MAP1B, ALPK3, ADAMTS5, ADAMTS4, KATNAL2, LSMEM1, PALM3, SPCS2P4, PRKAR1AP1, OR2R1P, SMIM20, AC007319.1, AL590560.1 and AC100810.3. The marker with liver metastasis specificity is identified in colorectal cancer exosome RNA, the effect of the marker in tumor cell migration is defined through cross validation, the marker can be used for predicting the risk of liver metastasis, potential molecular targets can be provided for follow-up targeted intervention research, and the application value of the marker is expanded.

The invention discloses application of LRP2 as a marker and a marker combination in preparation of a product for evaluating colorectal cancer liver metastasis risk, and belongs to the technical field of molecular biomedicine. The LRP2 is used as the marker for evaluating the liver metastasis risk of the colorectal cancer patient, and has the characteristics of high specificity, sensitivity and accuracy.

This invention provides the application of GCKR and its inhibitors in the preparation of drugs for treating pancreatic cancer, belonging to the field of biomedical technology. The application of GCKR and its inhibitors in the preparation of drugs for treating pancreatic cancer reveals for the first time that GCKR is a key metabolic switch driving liver metastasis in pancreatic cancer, and that high expression of the GCKR gene can promote the growth and liver metastasis of pancreatic cancer in mice. The proliferation, invasion, and migration abilities of pancreatic cancer cells in the GCKR low-expression group were significantly lower than those in the normal control group. Using a pancreatic cancer orthotopic xenograft model constructed in highly immunodeficient mice, the invention demonstrated in vivo that knocking out GCKR can inhibit the growth of pancreatic cancer, indicating that GCKR inhibitors block the progression of pancreatic cancer by downregulating GCKR; conversely, overexpression plasmids that promote GCKR expression can upregulate GCKR expression and promote pancreatic cancer progression. This provides a new application of GCKR and offers new ideas for the treatment of pancreatic cancer.

The invention discloses a colorectal cancer liver metastasis risk screening and evaluating method and system in the technical field of medical systems. The system comprises an acquisition module, a serum measurement and calculation module, a peripheral blood circulating tumor cell measurement and calculation module, a molecular marker measurement and calculation module, a probability classification module, a probability judgment module and an evaluation result output module. The probability judgment module is used for evaluating whether the liver metastasis condition exists in the body of the patient or not, and the evaluation content comprises the following steps; when X is equal to P, the serum tumor marker accounts for 5%, and the addition amount of X is greater than P0.1 by 2%, so that the addition amount is increased to 20%; when peripheral blood circulating tumor cells are detected in the blood of the patient, 60% is calculated; when Y is equal to P1, the molecular marker accounts for 5%, and Y is greater than P1 0.1 and is added by 2%, so that Y is increased to 20%. The method is simple and easy to operate, and the probability value of liver metastasis is accurately judged by combining data information of serum tumor markers, peripheral blood circulating tumor cells and molecular markers.

The invention discloses a preparation method of biodegradable alginate microspheres and a composition of the biodegradable alginate microspheres. The biodegradable alginate microspheres are used for treating at least one of the following diseases: hepatocellular carcinoma, colorectal hepatic metastasis, parangganglioma hepatic metastasis, neuroendocrine hepatic metastasis, gastrointestinal hepatic metastasis, mammary gland hepatic metastasis, melanoma hepatic metastasis, pancreatic hepatic metastasis, bile duct cancer hepatic metastasis, colorectal pulmonary metastasis and kidney pulmonary metastasis. Cirrhosis-associated thrombocytopenia, metastatic extrahepatic cholangiocarcinoma, glioblastoma, renal cell carcinoma, prostate cancer, and hysteromyoma. In some embodiments, the preparation method of the biodegradable alginate microspheres can utilize a microfluidic box.